CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

被引：18
|
作者：
Agha, Mounzer E.
Cohen, Adam D.
Madduri, Deepu
Cohen, Yael C.
Delforge, Michel
Hillengass, Jens
Goldschmidt, Hartmut
Weisel, Katja
Raab, Marc-Steffen
Scheid, Christof
Schecter, Jordan Mark
De Braganca, Kevin C.
Varsos, Helen
Wang, Liwei
Vogel, Martin
Carrasco-Alfonso, Marlene
Akram, Muhammad
Wu, Xiaoling
Nesheiwat, Tonia
Einsele, Hermann
机构：
[1] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Mt Sinai Med Ctr, New York, NY 10029 USA
[4] Tel Aviv Univ, Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel
[5] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[6] Univ Ziekenhuizen Leuven, Leuven, Belgium
[7] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[8] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[9] Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[10] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[11] Univ Hosp Heidelberg, Heidelberg, Germany
[12] Univ Cologne, Cologne, Germany
[13] Janssen R&D, Raritan, NJ USA
[14] Janssen Global Serv LLC, Raritan, NJ USA
[15] Legend Biotech USA Inc, Piscataway, NJ USA
[16] Legend Biotech USA Inc, Somerset, NJ USA
[17] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8013
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1-3 prior lines of therapy: Initial results from CARTITUDE-2
    Cohen, Adam
    Agha, Mounzer
    Madduri, Deepu
    Cohen, Yael
    Delforge, Michel
    Hillengass, Jens
    Goldschmidt, Hartmut
    Weisel, Katja
    Raab, Marc-Steffen
    Scheid, Christoph
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Varsos, Helen
    Wang, Liwei
    Vogel, Martin
    Carrasco-Alfonso, Marlene
    Akram, Muhammad
    Wu, Xiaoling
    Nesheiwat, Tonia
    Einsele, Hermann
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S15 - S15
  • [2] Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
    Van de Donk, Niels W. C. J.
    Agha, Mounzer
    Cohen, Adam D.
    Cohen, Yael C.
    Anguille, Sebastien
    Kerre, Tessa
    Roeloffzen, Wilfried W. H.
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Jackson, Carolyn C.
    Varsos, Helen
    Mistry, Pankaj
    Roccia, Tito
    Xu, Xiaoying
    Li, Katherine
    Zudaire, Enrique
    Corsale, Christina
    Akram, Muhammad
    Geng, Dong
    Pacaud, Lida
    Sonneveld, Pieter
    Zweegman, Sonja
    BLOOD, 2022, 140 : 7536 - 7537
  • [3] Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.
    van de Donk, Niels W. C. J.
    Agha, Mounzer E.
    Cohen, Adam D.
    Cohen, Yael C.
    Anguille, Sebastien
    Kerre, Tessa
    Roeloffzen, Wilfried
    Schecter, Jordan Mark
    De Braganca, Kevin C.
    Varsos, Helen
    Mistry, Pankaj
    Roccia, Tito
    Zudaire, Enrique
    Corsale, Christina
    Akram, Muhammad
    Geng, Dong
    Nesheiwat, Tonia
    Bubuteishvili-Pacaud, Lida
    Sonneveld, Pieter
    Zweegman, Sonja
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1-3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.
    Einsele, Hermann
    Cohen, Adam D.
    Delforge, Michel
    Hillengass, Jens
    Goldschmidt, Hartmut
    Weisel, Katja
    Raab, Marc-Steffen
    Scheid, Christof
    Schecter, Jordan Mark
    De Braganca, Kevin C.
    Varsos, Helen
    Yeh, Tzu-Min
    Mistry, Pankaj
    Roccia, Tito
    Corsale, Christina
    Akram, Muhammad
    Bubuteishvili-Pacaud, Lida
    Nesheiwat, Tonia
    Agha, Mounzer E.
    Cohen, Yael C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy
    Agha, Mounzer
    van de Donk, Niels W. C. J.
    Cohen, Adam D.
    Cohen, Yael C.
    Anguille, Sebastien
    Kerre, Tessa
    Roeloffzen, Wilfried
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Varsos, Helen
    Mistry, Pankaj
    Roccia, Tito
    Zudaire, Enrique
    Corsale, Christina
    Akram, Muhammed
    Geng, Dong
    Nesheiwat, Tonia
    Pacaud, Lida
    Sonneveld, Pieter
    Zweegman, Sonja
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S408 - S409
  • [6] Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2
    Cohen, Yael C.
    Cohen, Adam D.
    Delforge, Michel
    Hillengass, Jens
    Goldschmidt, Hartmut
    Weisel, Katja
    Raab, Marc-Steffen
    Scheid, Christof
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Varsos, Helen
    Yeh, Tzu-min
    Wang, Liwei
    Vogel, Martin
    Corsale, Christina
    Akram, Muhammad
    Pacaud, Lida
    Nesheiwat, Tonia
    Agha, Mounzer
    Einsele, Hermann
    BLOOD, 2021, 138 : 3866 - +
  • [7] CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in LenalidomideRefractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)
    Hillengass, Jens
    Cohen, Adam D.
    Delforge, Michel
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Raab, Marc-Steffen
    Scheid, Christof
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Varsos, Helen
    Yeh, Tzu-min
    Mistry, Pankaj
    Roccia, Tito
    Corsale, Christina
    Akram, Muhammad
    Pacaud, Lida
    Nesheiwat, Tonia
    Agha, Mounzer
    Cohen, Yael C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S411 - S411
  • [8] CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMADIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
    van de Donk, Niels
    Agha, Mounzer
    Cohen, Adam D.
    Cohen, Yael C.
    Anguille, Sebastien
    Kerre, Tessa
    Roeloffzen, Wilfried
    Madduri, Deepu
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Jackson, Carolyn C.
    Varsos, Helen
    Mistry, Pankaj
    Roccia, Tito
    Xu, Xiaoying
    Li, Katherine
    Zudaire, Enrique
    Corsale, Christina
    Akram, Muhammad
    Geng, Dong
    Pacaud, Lida
    Sonneveld, Pieter
    Zweegman, Sonja
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 110 - 111
  • [9] CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy
    Van de Donk, Niels W. C. J.
    Delforge, Michel
    Agha, Mounzer
    Cohen, Adam D.
    Cohen, Yael C.
    Hillengass, Jens
    Anguille, Sebastien
    Kerre, Tessa
    Roeloffzen, Wilfried
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Varsos, Helen
    Wang, Liwei
    Vogel, Martin
    Zudaire, Enrique
    Corsale, Christina
    Akram, Muhammad
    Geng, Dong
    Nesheiwat, Tonia
    Pacaud, Lida
    Sonneveld, Pieter
    Zweegman, Sonja
    BLOOD, 2021, 138
  • [10] Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and prior noncellular anti-BCMA therapy: CARTITUDE-2 cohort C
    Cohen, Adam
    Cohen, Yael
    Suvannasankha, Attaya
    van de Donk, Niels
    San-Miguel, Jesus
    De Braganca, Kevin
    Jackson, Carolyn
    Schecter, Jordan
    Vlummens, Philip
    Varsos, Helen
    Corsale, Christina
    Mistry, Pankaj
    Song, Qingxuan
    Roccia, Tito
    Geng, Dong
    Zhu, Jieqing
    Akram, Muhammad
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S167 - S168
12345